FDA Approves First mRNA Flu Vaccine But Limits Use to Older Adults

— Approval is only for people 50 years or older

August 6, 2026

• 2 min read

The FDA approved the trivalent flu vaccine mRNA-1010 (mFLUSIVA) for use in all adults age 50 years or older, Moderna announced on Wednesday. It is the first approved flu vaccine to use the mRNA technology that sped COVID-19 vaccine development.

Moderna received traditional approval in adults ages 50 to 64 years; accelerated approval was granted for those 65 and older, with a postmarketing effectiveness study planned for that population.

FDA Approves First mRNA Flu Vaccine But Limits Use to Older Adults

Other newsrooms on this story

Related reading

FDA approves new mRNA-based flu vaccine - UPI.com

FDA approves first mRNA-based flu vaccine | CNN

FDA Approves First mRNA Flu Vaccine For Older Adults

FDA approves first ever mRNA flu vaccine

FDA approves 1st mRNA flu shot, from Moderna

Medicines watchdog approves first-ever mRNA-based flu shot in the US